Read by QxMD icon Read

Gallium 68

Robert M Hicks, Jeffry P Simko, Antonio C Westphalen, Hao G Nguyen, Kirsten L Greene, Li Zhang, Peter R Carroll, Thomas A Hope
Purpose To compare the diagnostic accuracy of gallium 68 (68 Ga)-labeled prostate-specific membrane antigen (PSMA)-11 PET/MRI with that of multiparametric MRI in the detection of prostate cancer. Materials and Methods The authors performed a retrospective study of men with biopsy-proven prostate cancer who underwent simultaneous 68 Ga-PSMA-11 PET/MRI before radical prostatectomy between December 2015 and June 2017. The reference standard was whole-mount pathologic examination. Readers were blinded to radiologic and pathologic findings...
September 18, 2018: Radiology
Arun Sasikumar, Ajith Joy, Ambikalmajan M R Pillai, Karuna E Oommen, Sudin Somarajan, Vikraman Kaithavelil Raman, Renu Thomas, Dhanya Dinesh
OBJECTIVE: To assess the feasibility of gallium 68 (Ga)-prostate specific membrane antigen (PSMA) PET/computed tomography (CT) to identify patients who truly harbor clinically significant prostate cancer (PCa) in a cohort of patients with clinical and biochemical/radiological suspicion of PCa. PATIENTS AND METHODS: A total of 118 patients with suspected PCa who underwent Ga-PSMA PET/CT between May 2015 and June 2016 were prospectively included. Final decision on performing biopsy was left to the referring urologist after considering the clinical data, scan findings and discussion with the patient...
September 13, 2018: Nuclear Medicine Communications
Nader Hirmas, Akram Al-Ibraheem, Ken Herrmann, Abedalatif Alsharif, Haider Muhsin, Jamal Khader, Ali Al-Daghmin, Samer Salah
PURPOSE: In this retrospective study, we compared the diagnostic value of 68 Gallium prostate-specific membrane antigen positron emission tomography computed tomography ([68 Ga]PSMA PET/CT) in primary staging of patients with high-risk prostate cancer (PCa), in comparison to CT, magnetic resonance imaging (MRI), and bone scans, and we explored its overall impact on patients' management plan. PROCEDURES: Patients with pathological confirmation of PCa with high-risk disease were included in this study...
September 13, 2018: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Banafsheh Motazedi, Maziar Rahmani, James M Welch, Abbas Motazedi
A 77-year-old woman was diagnosed with pheochromocytoma followed by adrenalectomy at age 57. Hyperparathyroidism without osteoprosis was diagnosed at age 58. At age 75, Dual Energy X-ray Absoptiometry (DEXA) revealed osteoporosis and sestamibi scan showed a left parathyroid adenoma. Criteria for parathyroidectomy were met, and she underwent parathyroidectomy. Furthermore, she presented with haematochezia at age 75. An abdominal CT demonstrated a mass in the second portion of the duodenum. Additionally, octreoscan revealed somatostatin receptor positive tissue in the duodenum and Gallium 68 dotatate scan also showed a well-differentiated duodenal neuroendocrine tumour (NET)...
September 4, 2018: BMJ Case Reports
Eva Dyrberg, Helle W Hendel, Tri Hien Viet Huynh, Tobias Wirenfeldt Klausen, Vibeke B Løgager, Claus Madsen, Erik M Pedersen, Maria Pedersen, Henrik S Thomsen
OBJECTIVES: To determine the diagnostic accuracy of 68 gallium prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) in comparison with 18 F-fluoride-based PET/CT (NaF-PET/CT) and whole-body magnetic resonance imaging (WB-MRI) for the detection of bone metastases in patients with prostate cancer. METHODS: Sixty patients with prostate cancer were included in the period May 2016 to June 2017. The participants underwent three scans (index tests) within 30 days: a NaF-PET/CT, a WB-MRI and a PSMA-PET/CT...
August 21, 2018: European Radiology
Jasmine Shell, Xavier M Keutgen, Corina Millo, Naris Nilubol, Dhaval Patel, Samira Sadowski, Myriem Boufraqech, Lily Yang, Roxanne Merkel, Christine Atallah, Peter Herscovitch, Electron Kebebew
Aim: The study's aim was to determine the utility of 68-Gallium DOTATATE positron emission tomography (PET)-CT scanning in patients with carcinoid-like symptoms and negative anatomical imaging. Methods: Retrospective analysis of 22 of 196 patients with carcinoid-like symptoms and no evidence of primary neuroendocrine tumor (NET) based on anatomical imaging and endoscopy who underwent 68-Gallium DOTATATE PET-CT as part of a prospective clinical trial. Results: Of the biochemically positive patients (n = 11), 18% (n = 2) had additional evidence of NETs based on 68-Gallium DOTATATE PET-CT...
February 2018: International Journal of Endocrine Oncology
Stephen Thompson, Melissa E Rodnick, Jenelle Stauff, Janna Arteaga, Timothy J Desmond, Peter J H Scott, Benjamin L Viglianti
Radiolabeled erythrocytes have multiple applications in nuclear medicine, including blood pool imaging. Historically they have been labeled with SPECT radionuclides. A PET blood pool imaging agent is highly desirable as it would improve clinical applications with better image quality and resolution, higher sensitivity, and dynamic scanning capabilities. With the coming of age of modern 68 Ge/68 Ga generator systems, gallium-68 is now widely accessible. In this paper we describe an updated method for the preparation of 68 Ga-labeled erythrocytes and their preliminary use in rodent blood pool imaging...
March 1, 2018: MedChemComm
E David Crawford, Phillip J Koo, Neal Shore, Susan F Slovin, Raoul S Concepcion, Stephen J Freedland, Leonard G Gomella, Lawrence Karsh, Thomas E Keane, Paul Maroni, David Penson, Daniel P Petrylak, Ashley Ross, Vlad Mouraviev, Robert E Reiter, Chaitanya Divgi, Evan Y Yu
PURPOSE: The advanced prostate cancer therapeutic landscape has changed dramatically over the last several years, resulting in improved overall survival for patients with both castration-naive and castration-resistant disease. The evolution and development of novel next generation imaging (NGI) techniques will affect diagnostic and therapeutic decision-making. Clinicians must navigate when and which NGI techniques to use and how to adjust treatment strategies based upon their results, oftentimes in the absence of correlative therapeutic data...
August 2, 2018: Journal of Urology
Sean S Tanzey, Stephen Thompson, Peter Jh Scott, Allen F Brooks
Commercial 68 Ge/68 Ga generators provide a means to produce positron emission tomography agents on site without use of a cyclotron. This development has led to a rapid growth of academic literature and patents ongallium-68 (68 Ga). As 68 Ga positron emission tomography agents usually involve a targeting moiety attached to a metal chelator, the development lends itself to the investigation of theragnostic applications; the 68 Ga-based diagnostic is utilized to determine if the biological target is present and, if so, a therapeutic isotope (e...
September 2018: Pharmaceutical Patent Analyst
Dominik Summer, Andrea Kroess, Rudolf Woerndle, Christine Rangger, Maximilian Klingler, Hubertus Haas, Leopold Kremser, Herbert H Lindner, Elisabeth von Guggenberg, Clemens Decristoforo
Positron emission tomography (PET) with radiolabelled peptide-based tracers has attracted great interest in oncology over the past decades. The success of imaging is closely related to sufficient uptake of the radiotracer in malignant tissue and for this sufficient biological half-life, particularly in the bloodstream, is mandatory. Fast enzymatic degradation during circulation leading to insufficient imaging abilities of peptide-based radioligands remains a major issue. The design of multimeric constructs, bearing multiple targeting moieties, has been widely applied to improve target interaction...
2018: PloS One
E I Veliev, A A Tomilov, D A Goncharuk, A B Bogdanov, E N Golubtsova
INTRODUCTION: and aim. Most of the patients with biochemical recurrence after radical prostatectomy undergo salvage radiotherapy without guidance from imaging. In recent years, there has been an increasing role of Gallium-68 prostate specific membrane antigen (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) imaging in the management of prostate cancer. This study aimed to investigate diagnostic performance of 68Ga-PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy...
July 2018: Urologii︠a︡
Ismet Sarikaya, Abdelhamid Elgazzar, Ali Sarikaya, Mahmoud Alfeeli
Various positron emission tomography (PET) studies are available for prostate cancer which show various successes at demonstrating primary, recurrent, or metastatic tumor and assessing response to treatment. In this case report, we will present and compare pre- and post-therapy fluorodeoxyglucose, sodium fluoride, and gallium-68 prostate-specific membrane antigen PET images of a patient with prostate cancer.
July 2018: World Journal of Nuclear Medicine
Surbhi Prakash, Puja Panwar Hazari, Virendra Kumar Meena, Anil Kumar Mishra
A new S-alkylated cysteine-derivatized tumor targeting agent, 2,2'-(12-(2-((2-acetamido-2-carboxyethyl)thio)acetamido)-11,13-dioxo-1,4,7,10-tetraazacyclotridecane-4,7-diyl)diacetic acid was developed for positron emission tomography (PET) imaging. N -Acetyl cysteine (NAC) was conjugated to ATRIDAT as a specific targeting agent toward L-type and ASC amino acid transporter systems in the oncogenic cells. NAC was attached via S-alkylation to prevent its incorporation at undesired recognition sites affecting the signal-to-noise ratio...
June 30, 2018: ACS Omega
Erik de Blois, Rory M S de Zanger, Elisabeth Oehlke, Ho Sze Chan, Wouter A P Breeman
INTRODUCTION: 68 Ga-radiopharmaceuticals are common in the field of Nuclear Medicine to visualize receptor-mediated processes. In contrast to straightforward labeling procedures for clinical applications, preclinical in vitro and in vivo applications are hampered for reasons like e.g. volume restriction, activity concentration, molar activity and osmolality. Therefore, we developed a semi-automatic system specifically to overcome these problems. A difficulty appeared unexpectedly, as intrinsic trace metals derived from eluate (Zn, Fe and Cu) are concentrated as well in amounts that influence radiochemical yield and thus lower molar activity...
June 27, 2018: Nuclear Medicine and Biology
Alexander Wurzer, Julia Pollmann, Alexander Schmidt, Dominik Reich, Hans-Jürgen Wester, Johannes Notni
Radiopharmaceuticals targeting the enzyme prostate-specific membrane antigen (PSMA; synonyms: glutamate carboxypeptidase II, NAALADase; EC have recently emerged as powerful agents for diagnosis and therapy (theranostics) of prostate carcinoma (PCa). The radiation doses for therapeutic application of such compounds are limited by substantial uptakes in kidneys and salivary glands, with excess doses reportedly leading to radiotoxicity-related adverse effects, such as kidney insufficiency or xenostomia...
September 4, 2018: Molecular Pharmaceutics
Xiaozhu Wang, María de Guadalupe Jaraquemada-Peláez, Yang Cao, Jinhe Pan, Kuo-Shyan Lin, Brian O Patrick, Chris Orvig
An acyclic hexadentate oxine-derived chelating ligand, H2 hox, was investigated as an alternative to current chelators for 68 Ga. The straightforward preparation of H2 hox, involving only one or two steps, obviates the synthetic challenges associated with many reported 68 Ga chelators; it forms a Ga3+ complex of great stability (log K = 34.4) with a remarkably high gallium scavenging ability (pGa3+ = -log[Ga3+ free ] = 28.3, ([Ga3+ ] = 1 μM; [L x- ] = 10 μM; pH 7.4, and 25 °C)). Moreover, H2 hox coordinates 68 Ga quantitatively in 5 min at room temperature in ligand concentrations as low as 1 × 10-7 M, achieving an unprecedented high molar activity of 11 ± 1 mCi/nmol (407 ± 3...
July 10, 2018: Inorganic Chemistry
Stefan A Koerber, Leon Will, Clemens Kratochwil, Matthias F Haefner, Henrik Rathke, Christophe Kremer, Jonas Merkle, Klaus Herfarth, Klaus Kopka, Peter L Choyke, Tim Holland-Letz, Uwe Haberkorn, Juergen Debus, Frederik L Giesel
The present study analyzed the impact of Gallium-68 (68 Ga)-labeled prostate-specific membrane antigen-HBED-CC (68 Ga-PSMA-11) positron-emission tomography (PET)/computed tomography (CT) on radiotherapeutic management in a large cohort of men with primary or recurrent disease. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68 Ga-PSMA-11 PET/CT as well as conventional imaging. 50 patients were treatment naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery and 60 presented with recurrent PSA following definitive therapy...
July 5, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Ludwike W M van Kalmthout, Marnix G E H Lam, Bart de Keizer, Gerard C Krijger, Tessa F T Ververs, Rememrt de Roos, Arthur J A T Braat
BACKGROUND: External cooling of the salivary glands is advised to prevent xerostomia in lutetium-177-PSMA treatment for advanced prostate cancer. Since evidence addressing this subject is sparse, this study aims to determine impact of icepacks application on uptake in salivary glands. Eighty-nine patients referred for gallium-68-PSMA PET/CT for (re)staging of prostate cancer were prospectively included. Twenty-four patients were scanned with unilateral (solely left-sided) icepacks; 20 with bilateral icepacks; 45 without icepacks...
July 3, 2018: EJNMMI Research
Kristen M Anderson, Christopher V Barback, Zhengtao Qin, David J Hall, Carl K Hoh, David R Vera, Michael T McHale
Molecular imaging with a fluorescent version of Tilmanocept may permit an accurate and facile detection of sentinel nodes of endometrial cancer. Tilmanocept accumulates in sentinel lymph nodes (SLN) by binding to a cell surface receptor unique to macrophages and dendritic cells. Four female Yorkshire pigs underwent cervical stromal injection of IRDye800-Tilmanocept, a molecular imaging agent tagged with near-infrared fluorescent dye and radiolabeled with gallium-68 and technetium-99m. PET/CT scans 1.5 hours post-injection provided pre-operative SLN mapping...
2018: PloS One
Rakhee Vatsa, Abhiram Gopalajois Ashwathanarayana, Jaya Shukla, Shashank Singh, Priya Bhusari, Rajender Kumar, Harmandeep Singh, Bhagwant Rai Mittal
The gamut of gallium labeled radiopharmaceuticals contributes to augmented variety in molecular imaging approach for in vivo identification of tumor characteristics. The spectrum ranges from somatostatin receptor based target-specific imaging agents, to those used for tumor imaging based on specific receptor types extending into ones used for therapeutic monitoring. The versatility of gallium chemistry provides the needed advantage for imaging which is further exploited in clinical practice influences the specificity of tumor imaging...
July 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"